Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Carlsson SV, Talala KM, Lilja H, Denis LJ, Recker F, Paez A, Puliti D, Villers A, Rebillard X, Kilpeläinen TP, Stenman UH, Godtman RA, Stinesen Kollberg K, Moss SM, Kujala P, Taari K, Huber A, van der Kwast T, Heijnsdijk EA, Bangma C, De Koning HJ, Schröder FH, Auvinen A; ERSPC investigators.

Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.

PMID:
30824296
2.

Circadian genes and risk of prostate cancer: Findings from the EPICAP study.

Wendeu-Foyet MG, Koudou Y, Cénée S, Trétarre B, Rébillard X, Cancel-Tassin G, Cussenot O, Boland A, Bacq D, Deleuze JF, Lamy PJ, Mulot C, Laurent-Puig P, Truong T, Menegaux F.

Int J Cancer. 2019 Oct 1;145(7):1745-1753. doi: 10.1002/ijc.32149. Epub 2019 Feb 12.

PMID:
30665264
3.

[Short version of recommendations for enhanced recovery program (ERP) for cystectomy: Technical measures].

Poinas G, Blache JL, Kassab-Chahmi D, Evrard PL, Artus PM, Alfonsi P, Rébillard X, Beaussier M, Cerantola Y, Coloby P, Drapier É, Houédé N, Masson-Lecomt A, Rouprêt M, Le Normand L, Gamé X, Bosset PO, Delaunay L, Fendler JP, Ecoffey C, Cuvelier G.

Prog Urol. 2019 Feb;29(2):63-75. doi: 10.1016/j.purol.2018.12.002. Epub 2019 Jan 8. Review. French.

PMID:
30635149
4.

[French ccAFU guidelines - Update 2018-2020: Prostate cancer].

Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont-Hankard G, Mongiat-Artus P, Ploussard G, Mathieu R, Brureau L, Ouzzane A, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Rebillard X, Lebret T, Soulié M, Renard Penna R, Méjean A.

Prog Urol. 2018 Nov;28(12S):S79-S130. doi: 10.1016/j.purol.2018.08.011. Epub 2018 Nov 2. Review. French.

PMID:
30392712
5.

Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study.

Lavalette C, Trétarre B, Rebillard X, Lamy PJ, Cénée S, Menegaux F.

Oncotarget. 2018 Oct 2;9(77):34485-34494. doi: 10.18632/oncotarget.26128. eCollection 2018 Oct 2.

6.

[Place of partial nephrectomy assisted by robot: Review of the literature at the time of a request for a specific nomenclature].

Poinas G, Long JA, Rébillard X, Descotes JL.

Prog Urol. 2018 Dec;28(16):890-899. doi: 10.1016/j.purol.2018.08.012. Epub 2018 Oct 2. Review. French.

PMID:
30290985
7.

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations.

Pujol P, Vande Perre P, Faivre L, Sanlaville D, Corsini C, Baertschi B, Anahory M, Vaur D, Olschwang S, Soufir N, Bastide N, Amar S, Vintraud M, Ingster O, Richard S, Le Coz P, Spano JP, Caron O, Hammel P, Luporsi E, Toledano A, Rebillard X, Cambon-Thomsen A, Putois O, Rey JM, Hervé C, Zorn C, Baudry K, Galibert V, Gligorov J, Azria D, Bressac-de Paillerets B, Burnichon N, Spielmann M, Zarca D, Coupier I, Cussenot O, Gimenez-Roqueplo AP, Giraud S, Lapointe AS, Niccoli P, Raingeard I, Le Bidan M, Frebourg T, Rafii A, Geneviève D.

Eur J Hum Genet. 2018 Dec;26(12):1732-1742. doi: 10.1038/s41431-018-0224-1. Epub 2018 Aug 8.

PMID:
30089825
8.

Night work and prostate cancer risk: results from the EPICAP Study.

Wendeu-Foyet MG, Bayon V, Cénée S, Trétarre B, Rébillard X, Cancel-Tassin G, Cussenot O, Lamy PJ, Faraut B, Ben Khedher S, Léger D, Menegaux F.

Occup Environ Med. 2018 Aug;75(8):573-581. doi: 10.1136/oemed-2018-105009. Epub 2018 Jun 19.

9.

Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study.

Lamy PJ, Trétarre B, Rebillard X, Sanchez M, Cénée S, Ménégaux F.

Oncotarget. 2018 May 4;9(34):23661-23669. doi: 10.18632/oncotarget.25320. eCollection 2018 May 4.

10.

Prostatitis, other genitourinary infections and prostate cancer risk: Influence of non-steroidal anti-inflammatory drugs? Results from the EPICAP study.

Doat S, Marous M, Rebillard X, Trétarre B, Lamy PJ, Soares P, Delbos O, Thuret R, Segui B, Cénée S, Menegaux F.

Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31565. [Epub ahead of print]

11.

[Postoperative C-reactive protein is a reliable marker to detect complications after radical cystectomy].

Trabelssi M, Thuret R, Droupy S, Costa P, Rebillard X, Poinas G.

Prog Urol. 2018 Apr;28(5):282-290. doi: 10.1016/j.purol.2017.12.015. Epub 2018 Feb 1. French.

PMID:
29366634
12.

[Rates of total and free PSA prescriptions in France (2012-2014)].

Tuppin P, Leboucher C, Peyre-Lanquar G, Lamy PJ, Gabach P, Rébillard X.

Presse Med. 2017 Oct;46(10):e237-e247. doi: 10.1016/j.lpm.2017.04.015. Epub 2017 Oct 12. French.

PMID:
29031682
13.

Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study.

Doat S, Cénée S, Trétarre B, Rebillard X, Lamy PJ, Bringer JP, Iborra F, Murez T, Sanchez M, Menegaux F.

Cancer Med. 2017 Oct;6(10):2461-2470. doi: 10.1002/cam4.1186. Epub 2017 Sep 21.

14.

Radium 223 dichloride for prostate cancer treatment.

Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houédé N.

Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. doi: 10.2147/DDDT.S122417. eCollection 2017. Review.

15.

Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.

Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I, Murez T, Schlageter MH, Rouvière O, Kassab-Chahmi D, Rozet F, Descotes JL, Rébillard X.

Eur Urol Focus. 2018 Dec;4(6):790-803. doi: 10.1016/j.euf.2017.02.017. Epub 2017 Mar 7.

PMID:
28753865
16.

[Robot assisted radical prostatectomy: What are the evidences at the time of a specific funding?]

Long JA, Poinas G, Fiard G, Leprêtre M, Delaitre-Bonnin C, Rébillard X, Descotes JL.

Prog Urol. 2017 Mar;27(3):146-157. doi: 10.1016/j.purol.2016.12.010. Epub 2017 Feb 4. Review. French.

PMID:
28169123
17.

[CCAFU french national guidelines 2016-2018 on prostate cancer].

Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont G, Mongiat-Artus P, Ouzzane A, Ploussard G, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Lebret T, Rebillard X, Soulié M, Renard-Penna R, Méjean A.

Prog Urol. 2016 Nov;27 Suppl 1:S95-S143. doi: 10.1016/S1166-7087(16)30705-9. Review. French.

PMID:
27846936
18.

[Urinary incontinence and sexual dysfunction after treatment of localized prostate cancer: Results from a population aged less than 65years old].

Bessaoud F, Orsini M, Iborra F, Rebillard X, Faix A, Soulier M, Daurès JP, Trétarre B.

Bull Cancer. 2016 Oct;103(10):829-840. doi: 10.1016/j.bulcan.2016.09.011. Epub 2016 Sep 29. French.

PMID:
27692730
19.

Technique of Injection of Hyaluronic Acid as a Prostatic Spacer and Fiducials Before Hypofractionated External Beam Radiotherapy for Prostate Cancer.

Boissier R, Udrescu C, Rebillard X, Terrier JE, Faix A, Chapet O, Azria D, Devonec M, Paparel P, Ruffion A.

Urology. 2017 Jan;99:265-269. doi: 10.1016/j.urology.2016.09.045. Epub 2016 Oct 8.

PMID:
27725233
20.

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.

Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F.

Cancer Treat Rev. 2017 Apr;55:211-217. doi: 10.1016/j.ctrv.2016.09.008. Epub 2016 Sep 10. Review.

21.

[The level of evidence for the use of biomarkers in the early detection of prostate cancer].

Lamy PJ, Gauchez AS, Salomon L, Haugh M, Ceraline J, Fulla Y, Georges A, Larré S, Loric S, Luporsi E, Martin PM, Mazerolles C, Molinié V, Mongiat-Artus P, Piffret J, Thuillier F, Perrin P, Rebillard X; Groupe de biologie de la prostate.

Ann Biol Clin (Paris). 2016 Mar-Apr;74(2):227-32. doi: 10.1684/abc.2016.1128. Review. French.

22.

Prostate cancer: net survival and cause-specific survival rates after multiple imputation.

Morisot A, Bessaoud F, Landais P, Rébillard X, Trétarre B, Daurès JP.

BMC Med Res Methodol. 2015 Jul 28;15:54. doi: 10.1186/s12874-015-0048-4.

23.

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.

Houédé N, Beuzeboc P, Gourgou S, Tosi D, Moise L, Gravis G, Delva R, Fléchon A, Latorzeff I, Ferrero JM, Oudard S, Tartas S, Laguerre B, Topart D, Roubaud G, Agherbi H, Rebillard X, Azria D.

BMC Cancer. 2015 Apr 4;15:222. doi: 10.1186/s12885-015-1257-2.

24.

Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey.

Ariane MM, Ploussard G, Rebillard X, Malavaud B, Rischmann P, Hennequin C, Mongiat-Artus P.

World J Urol. 2015 Nov;33(11):1741-7. doi: 10.1007/s00345-015-1543-2. Epub 2015 Mar 31.

PMID:
25822706
25.

Mannose-6-phosphate receptor: a target for theranostics of prostate cancer.

Vaillant O, El Cheikh K, Warther D, Brevet D, Maynadier M, Bouffard E, Salgues F, Jeanjean A, Puche P, Mazerolles C, Maillard P, Mongin O, Blanchard-Desce M, Raehm L, Rébillard X, Durand JO, Gary-Bobo M, Morère A, Garcia M.

Angew Chem Int Ed Engl. 2015 May 11;54(20):5952-6. doi: 10.1002/anie.201500286. Epub 2015 Mar 20.

PMID:
25802144
26.

Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M.

Eur Urol. 2015 Nov;68(5):885-90. doi: 10.1016/j.eururo.2015.02.042. Epub 2015 Mar 16.

27.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators.

Lancet. 2014 Dec 6;384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6.

28.

Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy.

Bruyère F, Malavaud S, Bertrand P, Decock A, Cariou G, Doublet JD, Bernard L, Bugel H, Conquy S, Sotto A, Boiteux JP, Pogu B, Rebillard X, Mongiat-Artus P, Coloby P.

J Urol. 2015 Jan;193(1):145-50. doi: 10.1016/j.juro.2014.07.086. Epub 2014 Jul 22.

PMID:
25063492
29.

Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France.

Menegaux F, Anger A, Randrianasolo H, Mulot C, Laurent-Puig P, Iborra F, Bringer JP, Leizour B, Thuret R, Lamy PJ, Rébillard X, Trétarre B; EPICAP Study Group.

BMC Cancer. 2014 Feb 19;14:106. doi: 10.1186/1471-2407-14-106.

30.

[CCAFU Recommendations 2013: Prostate cancer].

Salomon L, Bastide C, Beuzeboc P, Cormier L, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Ploussard G, Renard-Penna R, Rozet F, Azria D, Coloby P, Molinié V, Ravery V, Rebillard X, Richaud P, Villers A, Soulié M; Les membres du CCAFU.

Prog Urol. 2013 Nov;23 Suppl 2:S69-101. doi: 10.1016/S1166-7087(13)70048-4. French.

PMID:
24485295
31.

[Incidence and mortality of urological cancers in 2012 in France].

Rébillard X, Grosclaude P, Leone N, Velten M, Coureau G, Villers A, Irani J, Lebret T, Rigaud J, Pfister C, Patard JJ, Richaud P, Salomon L, Coloby P, Soulié M; Les membres du CCAFU.

Prog Urol. 2013 Nov;23 Suppl 2:S57-65. doi: 10.1016/S1166-7087(13)70047-2. French.

PMID:
24485294
32.

Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer.

El Demery M, Demirdjian-Sarkissian G, Thezenas S, Jacot W, Laghzali Y, Darbouret B, Culine S, Rebillard X, Lamy PJ.

Clin Transl Med. 2014 Oct 28;3:31. doi: 10.1186/s40169-014-0031-4. eCollection 2014.

33.

Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.

Azria D, Riou O, Rebillard X, Thezenas S, Thuret R, Fenoglietto P, Pouessel D, Culine S.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):853-9. doi: 10.1016/j.ijrobp.2013.11.016. Epub 2013 Dec 21.

34.

Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study.

Ploussard G, Staerman F, Pierrevelcin J, Larue S, Villers A, Ouzzane A, Bastide C, Gaschignard N, Buge F, Pfister C, Bonniol R, Rebillard X, Fadli S, Mottet N, Saint F, Saad R, Beauval JB, Roupret M, Audenet F, Peyromaure M, Delongchamps NB, Vincendeau S, Fardoun T, Rigaud J, Soulie M, Salomon L; Committee of Cancerology (CCAFU) of the Association of French Urology (AFU).

World J Urol. 2014 Oct;32(5):1331-8. doi: 10.1007/s00345-013-1214-0. Epub 2013 Nov 24.

PMID:
24270970
35.

[Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].

Lamy PJ, Montels F, Tosi D, Leizour B, Bascoul-Mollevi C, Castan F, Roques S, Nielloud F, Rebillard X.

Ann Biol Clin (Paris). 2013 Sep-Oct;71(5):537-44. doi: 10.1684/abc.2013.0894. French.

36.

Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages.

Descotes F, Dessen P, Bringuier PP, Decaussin M, Martin PM, Adams M, Villers A, Lechevallier E, Rebillard X, Rodriguez-Lafrasse C, Devonec M, Paparel P, Perrin P, Lazar V, Ruffion A.

BJU Int. 2014 Feb;113(2):333-42. doi: 10.1111/bju.12364. Epub 2013 Oct 31.

37.

Targeting multiplicity: the key factor for anti-cancer nanoparticles.

Gary-Bobo M, Vaillant O, Maynadier M, Basile I, Gallud A, El Cheikh K, Bouffard E, Morère A, Rébillard X, Puche P, Nirdé P, Garcia M.

Curr Med Chem. 2013;20(15):1946-55. Review.

PMID:
23409718
38.

[Status and medicolegal implications in France pT0 stage of prostate cancer: a study by the CC-AFU].

Bessede T, Soulié M, Mottet N, Rebillard X, Peyromaure M, Ravery V, Salomon L; le sous-comité prostate du CC-AFU.

Prog Urol. 2012 Dec;22(16):1021-5. doi: 10.1016/j.purol.2012.07.018. Epub 2012 Sep 7. French.

PMID:
23178099
39.

[Sexuality and prostate cancer].

Colson MH, Lechevallier E, Rambeaud JJ, Alimi JC, Faix A, Gravis G, Hannoun-Levi JM, Quintens H, Rébillard X, Droupy S.

Prog Urol. 2012 Sep;22 Suppl 2:S72-92. doi: 10.1016/S1166-7087(12)70039-8. French.

PMID:
23098793
40.

[Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].

Rouprêt M, Neuzillet Y, Larré S, Pignot G, Coloby P, Rébillard X, Mongiat-Artus P, Chartier-Kastler E, Soulié M, Pfister C; Comité de cancérologie de l'Association française d'urologie.

Prog Urol. 2012 Nov;22(15):920-31. doi: 10.1016/j.purol.2012.05.002. Epub 2012 Jun 15. French.

PMID:
23102014
41.

[Circulating tumor cells and advanced prostate cancer].

Murez T, Droupy S, Rebillard X, Alix-Panabieres C.

Bull Cancer. 2012 Jul;99 Suppl 1:S4-15. doi: 10.1684/bdc.2012.1565. Review. French.

PMID:
22569300
42.

Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center.

Riou O, Fenoglietto P, Laliberté B, Menkarios C, Llacer Moscardo C, Hay MH, Ailleres N, Dubois JB, Rebillard X, Azria D.

ISRN Urol. 2012;2012:391705. doi: 10.5402/2012/391705. Epub 2012 Mar 20.

43.

Prostate-cancer mortality at 11 years of follow-up.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators.

N Engl J Med. 2012 Mar 15;366(11):981-90. doi: 10.1056/NEJMoa1113135. Erratum in: N Engl J Med. 2012 May 31;366(22):2137.

44.

[CAPURO survey on quality of life of urologists in 2009].

Moreau JL, Rébillard X, Coloby P.

Prog Urol. 2012 Feb;22(2):120-6. doi: 10.1016/j.purol.2011.07.012. Epub 2011 Sep 16. French.

PMID:
22284597
45.

Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.

Ploussard G, Masson-Lecomte A, Beauval JB, Ouzzane A, Bonniol R, Buge F, Fadli S, Rouprêt M, Rebillard X, Gaschignard N, Pfister C, Villers A, Soulié M, Salomon L; Prostate Cancer Committee of the French Association of Urology.

Urology. 2011 Sep;78(3):607-13. doi: 10.1016/j.urology.2011.05.021. Epub 2011 Jul 23.

PMID:
21783233
46.

[A survey from the French Urology Association about sick leave prescriptions by 145 surgeons].

Fassier JB, Charbotel B, Fort E, Rebillard X, Moreau JL, Borgogno C, Devonec M, Paparel P, Ruffion A.

Prog Urol. 2011 Jul;21(7):479-85. doi: 10.1016/j.purol.2011.02.001. Epub 2011 Mar 23. French.

PMID:
21693360
47.

Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry.

Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A.

BJU Int. 2011 Oct;108(8 Pt 2):E196-201. doi: 10.1111/j.1464-410X.2011.10091.x. Epub 2011 Feb 18.

48.

[Recommendations for best practice for prostate biopsy].

Ouzzane A, Coloby P, Mignard JP, Allegre JP, Soulie M, Rebillard X, Salomon L, Villers A; Committee of Infectious Diseases of the French Association of Urology (CIAFU); Committee of Cancerology of the French Association of Urology (CCAFU).

Prog Urol. 2011 Jan;21(1):18-28. doi: 10.1016/j.purol.2010.07.001. Epub 2010 Aug 7. Review. French.

PMID:
21193141
49.

[Recommendations Onco-Urology 2010: Prostate cancer].

Salomon L, Azria D, Bastide C, Beuzeboc P, Cormier L, Cornud F, Eiss D, Eschwège P, Gaschignard N, Hennequin C, Molinié V, Mongiat Artus P, Moreau JL, Péneau M, Peyromaure M, Ravery V, Rebillard X, Richaud P, Rischmann P, Rozet F, Staerman F, Villers A, Soulié M; Oncology Committee of the French Association of Urology (CCAFU).

Prog Urol. 2010 Nov;20 Suppl 4:S217-51. doi: 10.1016/S1166-7087(10)70042-7. French. No abstract available.

PMID:
21129644
50.

[Projected incidence and mortality from urologic cancer in France in 2010.].

Rébillard X, Grosclaude P, Lebret T, Patard JJ, Pfister C, Richaud P, Rigaud J, Salomon L, Soulié M.

Prog Urol. 2010 Nov;20 Suppl 4:S211-4. doi: 10.1016/S1166-7087(10)70041-5. French. No abstract available.

PMID:
21129643

Supplemental Content

Loading ...
Support Center